Reperfusion therapy

DEFINE PCI study one-year data show potential of treating residual ischemia to improve clinical outcomes for coronary stent patients

Retrieved on: 
Thursday, October 15, 2020
Circulatory system, Cardiovascular system, Clinical medicine, Aging-associated diseases, Heart diseases, Percutaneous coronary intervention, Interventional cardiology, Coronary artery disease, Angina, PCI, Instantaneous wave-free ratio, Reperfusion therapy

The DEFINE PCI study assessed the level of residual ischemia, or reduced blood flow to the heart muscle, found in patients after a percutaneous coronary intervention (PCI), an image-guided, minimally invasive treatment to open coronary artery blockages.

Key Points: 
  • The DEFINE PCI study assessed the level of residual ischemia, or reduced blood flow to the heart muscle, found in patients after a percutaneous coronary intervention (PCI), an image-guided, minimally invasive treatment to open coronary artery blockages.
  • The blinded acute data of DEFINE PCI revealed that 24% of patients with angiographically successful PCI still had residual ischemia.
  • The DEFINE PCI one-year data release shows that patients whose baseline ischemia was more effectively treated (post-PCI iFR 0.95) had improved outcomes and less recurrent angina (chest pain) at one year.
  • The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.

Otitopic Advances Asprihale® Into Pivotal PK/PD Study

Retrieved on: 
Wednesday, February 26, 2020
Pharmaceutical, Health, Clinical trials, Cardiology, Cardiovascular diseases, Reperfusion therapy, Management of acute coronary syndrome

Otitopic today announces that it is advancing towards its pivotal PK/PD study following discussions with the FDA.

Key Points: 
  • Otitopic today announces that it is advancing towards its pivotal PK/PD study following discussions with the FDA.
  • Asprihale is intended for emergency treatment to reduce the risk of vascular mortality in patients with suspected acute MI.
  • Asprihale has been developed for self-administration by the patient as emergency supportive therapy; after administration, the patient should seek immediate medical or hospital care.
  • Otitopic will continue working to advance the pivotal study to improve the lives of high- and intermediate-risk MI patients who need a better treatment option at the time of MI.

Getinge Opens New Acute Care Section in the Experience Center in Germany

Retrieved on: 
Wednesday, June 5, 2019
Medicine, Medical specialties, Clinical medicine, Cardiac surgery, Coronary artery bypass surgery, Coronary artery disease, Minimally invasive cardiac surgery, Reperfusion therapy

GETINGE, Sweden, June 5, 2019 /PRNewswire/ -- Getinge has opened up a brand new acute care section focused on Cardiovascular Procedures in one of its Experience Centers located in Rastatt, Germany.

Key Points: 
  • GETINGE, Sweden, June 5, 2019 /PRNewswire/ -- Getinge has opened up a brand new acute care section focused on Cardiovascular Procedures in one of its Experience Centers located in Rastatt, Germany.
  • Here, customers have the possibility to learn more about the solutions that Getinge provides to not only aid in the Coronary Artery Bypass Surgery (CABG) procedure but the entire continuum of care.
  • For more than 50 years, coronary artery bypass graft (CABG) surgery has been the standard of care for revascularization of patients with coronary artery disease.
  • With Cardiohelp and Cardiosave the patient can be stabilized before surgery while using the Pulsion advanced hemodynamic technology for monitoring", says Markus Stirner-Schilling, Senior Director Acute Care Therapies Global Commercial Operations at Getinge.